Package: sta310r 0.1.0

sta310r: Data Sets and Computer Exercises for the STA310 Survival Analysis Course

The data sets that accompany Collett (2023), "Modelling Survival Data in Medical Research" (4th edition), documented for the STA310 course at the University of Gothenburg, together with the computer exercises used in the course. The package focuses on the data sets, their documentation and the exercise vignettes.

Authors:Erik Bülow [aut, cre]

sta310r_0.1.0.tar.gz
sta310r_0.1.0.zip(r-4.7-any)sta310r_0.1.0.zip(r-4.6-any)sta310r_0.1.0.zip(r-4.5-any)
sta310r_0.1.0.tgz(r-4.6-any)sta310r_0.1.0.tgz(r-4.5-any)
sta310r_0.1.0.tar.gz(r-4.7-any)sta310r_0.1.0.tar.gz(r-4.6-any)
sta310r_0.1.0.tgz(r-4.6-emscripten)
manual.pdf |manual.html✨
DESCRIPTION |NEWS
card.svg |card.png
sta310r/json (API)

# Install 'sta310r' in R:
install.packages('sta310r', repos = c('https://eribul.r-universe.dev', 'https://cloud.r-project.org'))

Bug tracker:https://github.com/eribul/sta310r/issues

Pkgdown/docs site:https://eribul.github.io

Datasets:
  • aortic - Survival following aortic valve replacement
  • bladder - Recurrence of bladder cancer
  • bmt - Bone marrow transplantation in leukaemia patients
  • bmt_leukaemia - Bone marrow transplantation in the treatment of leukaemia
  • bmt_outcome - Patient outcome following bone marrow transplantation
  • breast - Prognosis for women with breast cancer
  • breast_rfs - Recurrence-free survival in breast cancer patients
  • cgd - Chronic granulomatous disease
  • cirrhosis - Data from a cirrhosis study
  • cirrhosis_cp - Data from a cirrhosis study
  • cirrhosis_lbr - Data from a cirrhosis study
  • d1.1 - Time to discontinuation of an intrauterine device
  • d1.2 - Prognosis for women with breast cancer
  • d1.3 - Survival of multiple myeloma patients
  • d1.4 - Comparison of two treatments for prostatic cancer
  • d10.1 - Prognosis for women with breast cancer
  • d10.2 - Prognosis for women with breast cancer
  • d10.3 - Survival of patients registered for a lung transplant
  • d10.4 - Survival following kidney transplantation
  • d11.1 - Recurrence of an ulcer
  • d11.2 - Survival of patients with gastric cancer
  • d11.3 - Survival of patients with gastric cancer
  • d11.4 - Comparisons between kidney transplant centres
  • d11.5 - Comparisons between kidney transplant centres
  • d11.6 - Comparisons between kidney transplant centres
  • d11.7 - Comparisons between kidney transplant centres
  • d11.8 - Comparisons between kidney transplant centres
  • d12.1 - Survival of liver transplant recipients
  • d12.2 - Survival of liver transplant recipients
  • d12.3 - Survival of liver transplant recipients
  • d12.4 - Survival of liver transplant recipients
  • d12.5 - Survival of liver transplant recipients
  • d12.6 - Survival of liver transplant recipients
  • d12.7 - Survival of laboratory mice with competing causes of death
  • d13.2 - Recurrence of mammary tumours in female rats
  • d13.3 - Clinical trial of tamoxifen in breast cancer patients
  • d13.4 - Patient outcome following bone marrow transplantation
  • d14.1 - Time to death while waiting for a liver transplant
  • d14.3 - Time to death while waiting for a liver transplant
  • d15.1 - Chronic active hepatitis
  • d15.2 - Chronic active hepatitis
  • d15.3 - Chronic active hepatitis
  • d16.1 - Time to discontinuation of an intrauterine device
  • d16.2 - Time to discontinuation of an intrauterine device
  • d16.3 - Time to discontinuation of an intrauterine device
  • d16.4 - Prognosis for women with breast cancer
  • d16.5 - Prognosis for women with breast cancer
  • d16.6 - Prognosis for women with breast cancer
  • d16.7 - Health evaluation and linkage to primary care
  • d2.1 - Pulmonary metastasis in patients with osteosarcoma
  • d2.10 - Time to discontinuation of an intrauterine device
  • d2.11 - Prognosis for women with breast cancer
  • d2.12 - Prognosis for women with breast cancer
  • d2.13 - Prognosis for women with breast cancer
  • d2.14 - Prognosis for women with breast cancer
  • d2.15 - Survival times of patients with melanoma
  • d2.16 - Survival times of patients with melanoma
  • d2.2 - Survival of multiple myeloma patients
  • d2.3 - Time to discontinuation of an intrauterine device
  • d2.4 - Time to discontinuation of an intrauterine device
  • d2.5 - Time to discontinuation of an intrauterine device
  • d2.6 - Survival of multiple myeloma patients
  • d2.7 - Time to discontinuation of an intrauterine device
  • d2.8 - Time to discontinuation of an intrauterine device
  • d2.9 - Time to discontinuation of an intrauterine device
  • d3.1 - Prognosis for women with breast cancer
  • d3.10 - Treatment of hypernephroma
  • d3.11 - Treatment of hypernephroma
  • d3.12 - Comparison of two treatments for prostatic cancer
  • d3.13 - Treatment of hypernephroma
  • d3.14 - Treatment of hypernephroma
  • d3.15 - Survival of multiple myeloma patients
  • d3.16 - Comparison of two treatments for prostatic cancer
  • d3.17 - Survival of multiple myeloma patients
  • d3.19 - Survival of multiple myeloma patients
  • d3.2 - Survival of multiple myeloma patients
  • d3.20 - Survival of multiple myeloma patients
  • d3.3 - Prognosis for women with breast cancer
  • d3.4 - Treatment of hypernephroma
  • d3.5 - Survival of multiple myeloma patients
  • d3.6 - Comparison of two treatments for prostatic cancer
  • d3.7 - Survival of multiple myeloma patients
  • d3.8 - Survival of multiple myeloma patients
  • d3.9 - Survival of multiple myeloma patients
  • d4.1 - Infection in patients on dialysis
  • d4.10 - Infection in patients on dialysis
  • d4.11 - Infection in patients on dialysis
  • d4.12 - Infection in patients on dialysis
  • d4.2 - Infection in patients on dialysis
  • d4.3 - Infection in patients on dialysis
  • d4.4 - Infection in patients on dialysis
  • d4.5 - Survival of multiple myeloma patients
  • d4.6 - Infection in patients on dialysis
  • d4.7 - Infection in patients on dialysis
  • d4.8 - Survival of multiple myeloma patients
  • d4.9 - Survival of multiple myeloma patients
  • d5.1 - Time to discontinuation of an intrauterine device
  • d5.10 - Treatment of hypernephroma
  • d5.11 - Chemotherapy in ovarian cancer patients
  • d5.12 - Chemotherapy in ovarian cancer patients
  • d5.13 - Prognosis for women with breast cancer
  • d5.14 - Prognosis for women with breast cancer
  • d5.15 - Comparison of two treatments for prostatic cancer
  • d5.16 - Survival of multiple myeloma patients
  • d5.17 - Prognosis for women with breast cancer
  • d5.2 - Time to discontinuation of an intrauterine device
  • d5.3 - Time to discontinuation of an intrauterine device
  • d5.4 - Time to discontinuation of an intrauterine device
  • d5.5 - Prognosis for women with breast cancer
  • d5.6 - Prognosis for women with breast cancer
  • d5.7 - Prognosis for women with breast cancer
  • d5.8 - Prognosis for women with breast cancer
  • d5.9 - A numerical illustration of two factors
  • d6.1 - Treatment of hypernephroma
  • d6.4 - Treatment of hypernephroma
  • d6.5 - Recurrence-free survival in breast cancer patients
  • d6.6 - Recurrence-free survival in breast cancer patients
  • d7.1 - Chemotherapy in ovarian cancer patients
  • d7.2 - Chemotherapy in ovarian cancer patients
  • d7.3 - Chemotherapy in ovarian cancer patients
  • d7.4 - Chemotherapy in ovarian cancer patients
  • d8.2 - Bone marrow transplantation in the treatment of leukaemia
  • d8.3 - Chemotherapy in ovarian cancer patients
  • d8.4 - Data from a cirrhosis study
  • d8.5 - Survival following aortic valve replacement
  • d8.6 - Survival following aortic valve replacement
  • d8.7 - Survival following aortic valve replacement
  • d8.8 - Survival following aortic valve replacement
  • d8.9 - Survival following aortic valve replacement
  • d9.1 - Recurrence of an ulcer
  • d9.4 - Recurrence of an ulcer
  • d9.5 - Recurrence of an ulcer
  • d9.6 - Recurrence of an ulcer
  • d9.7 - Recurrence of an ulcer
  • dataset_by_exercise - Data sets by Collett (2023) example
  • dialysis - Infection in patients on dialysis
  • ducks - Survival of black ducks
  • gastric - Survival of patients with gastric cancer
  • help - Health evaluation and linkage to primary care
  • hepatitis - Chronic active hepatitis
  • hyper - Treatment of hypernephroma
  • iud - Time to discontinuation of an intrauterine device
  • kidney - Survival following kidney transplantation
  • kidney_centres - Comparisons between kidney transplant centres
  • liver - Survival of liver transplant recipients
  • liver_wait - Time to death while waiting for a liver transplant
  • lung_transplant - Survival of patients registered for a lung transplant
  • melanoma - Survival times of patients with melanoma
  • mice - Survival of laboratory mice with competing causes of death
  • myeloma - Survival of multiple myeloma patients
  • numerical_illustration - A numerical illustration of two factors
  • ovarian - Chemotherapy in ovarian cancer patients
  • prostate - Comparison of two treatments for prostatic cancer
  • pulmonary - Pulmonary metastasis in patients with osteosarcoma
  • rats - Recurrence of mammary tumours in female rats
  • scottish_mbc_cohort - Synthetic Scottish metastatic breast cancer cohort
  • tamoxifen - Clinical trial of tamoxifen in breast cancer patients
  • ulcer - Recurrence of an ulcer

On CRAN:

Conda:

3.60 score 8 scripts 0 exports 0 dependencies

Last updated from:7b3cddc1d3 (on main). Checks:7 NOTE, 2 OK. Indexed: yes.

TargetResultTimeFilesSyslog
linux-develNOTE237
source / vignettesOK253
linux-releaseNOTE169
macos-releaseNOTE128
macos-oldrelNOTE120
windows-develNOTE173
windows-releaseNOTE132
windows-oldrelNOTE119
wasm-releaseOK146

Exports:

Dependencies:

Computer exercise 1: Describing and comparing survival data
Data and software | 1. From a clinical question to a time-to-event data set | 2. The empirical survivor function when there is no censoring | 3. Kaplan–Meier | 4. Hazard and cumulative hazard | 5. Comparing two groups | 6. Three or more groups
Rendered fromcs1-survival-data.Rmdusingknitr::rmarkdown

Last update: 2026-11-11
Started: 2026-11-09

Computer exercise 1: solutions
Rendered fromcs1-solutions.Rmdusingknitr::rmarkdown

Last update: 2026-11-10
Started: 2026-11-06

Getting started with sta310r
Overview | The data sets | Data sets by example | Computer exercises
Rendered fromsta310r.Rmdusingknitr::rmarkdown

Last update: 2026-11-09
Started: 2026-11-06

Data sets by exercise
The dX.Y aliases | Index by data set | Index by example | Data sets without a numbered example | Using the index in R | Reproducing the book's analyses
Rendered fromdatasets-by-exercise.Rmdusingknitr::rmarkdown

Last update: 2026-11-07
Started: 2026-11-07

Readme and manuals

Help Manual

Help pageTopics
Survival following aortic valve replacementaortic d8.5 d8.6 d8.7 d8.8 d8.9
Recurrence of bladder cancerbladder
Bone marrow transplantation in leukaemia patientsbmt
Bone marrow transplantation in the treatment of leukaemiabmt_leukaemia d8.2
Patient outcome following bone marrow transplantationbmt_outcome d13.4
Prognosis for women with breast cancerbreast d1.2 d10.1 d10.2 d16.4 d16.5 d16.6 d2.11 d2.12 d2.13 d2.14 d3.1 d3.3 d5.13 d5.14 d5.17 d5.5 d5.6 d5.7 d5.8
Recurrence-free survival in breast cancer patientsbreast_rfs d6.5 d6.6
Chronic granulomatous diseasecgd
Data from a cirrhosis study (baseline)cirrhosis d8.4
Data from a cirrhosis study (counting process format)cirrhosis_cp
Data from a cirrhosis study (log-bilirubin data)cirrhosis_lbr
Data sets by Collett (2023) exampledataset_by_exercise
Infection in patients on dialysisd4.1 d4.10 d4.11 d4.12 d4.2 d4.3 d4.4 d4.6 d4.7 dialysis
Survival of black ducksducks
Survival of patients with gastric cancerd11.2 d11.3 gastric
Health evaluation and linkage to primary cared16.7 help
Chronic active hepatitisd15.1 d15.2 d15.3 hepatitis
Treatment of hypernephromad3.10 d3.11 d3.13 d3.14 d3.4 d5.10 d6.1 d6.4 hyper
Time to discontinuation of an intrauterine device (IUD)d1.1 d16.1 d16.2 d16.3 d2.10 d2.3 d2.4 d2.5 d2.7 d2.8 d2.9 d5.1 d5.2 d5.3 d5.4 iud
Survival following kidney transplantationd10.4 kidney
Comparisons between kidney transplant centresd11.4 d11.5 d11.6 d11.7 d11.8 kidney_centres
Survival of liver transplant recipientsd12.1 d12.2 d12.3 d12.4 d12.5 d12.6 liver
Time to death while waiting for a liver transplantd14.1 d14.3 liver_wait
Survival of patients registered for a lung transplantd10.3 lung_transplant
Survival times of patients with melanomad2.15 d2.16 melanoma
Survival of laboratory mice with competing causes of deathd12.7 mice
Survival of multiple myeloma patientsd1.3 d2.2 d2.6 d3.15 d3.17 d3.19 d3.2 d3.20 d3.5 d3.7 d3.8 d3.9 d4.5 d4.8 d4.9 d5.16 myeloma
A numerical illustration of two factorsd5.9 numerical_illustration
Chemotherapy in ovarian cancer patientsd5.11 d5.12 d7.1 d7.2 d7.3 d7.4 d8.3 ovarian
Comparison of two treatments for prostatic cancerd1.4 d3.12 d3.16 d3.6 d5.15 prostate
Pulmonary metastasis in patients with osteosarcomad2.1 pulmonary
Recurrence of mammary tumours in female ratsd13.2 rats
Synthetic Scottish metastatic breast cancer cohortscottish_mbc_cohort
Clinical trial of tamoxifen in breast cancer patientsd13.3 tamoxifen
Recurrence of an ulcerd11.1 d9.1 d9.4 d9.5 d9.6 d9.7 ulcer